InsiderTrades

Form 4 for ROIV Roivant Sciences Ltd.

Accepted 2024-09-24 00:00:00 ET · period of report 2024-09-20 · accession 0001140361-24-041789 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2024-09-24 2024-09-23 ROIV Kumar Rakhi CAO M - OptEx $3.85 +250.0K 459.3K +119% +$962.5K
DT 2024-09-24 2024-09-20 ROIV Kumar Rakhi CAO F - Tax $11.97 -3,087 209.3K -1% -$37.0K
DT 2024-09-24 2024-09-23 ROIV Kumar Rakhi CAO S - Sale+OE $11.89 -250.0K 209.3K -54% -$2.97M
DT 2024-09-24 2024-09-23 ROIV Kumar Rakhi CAO M - OptEx $0.00 -250.0K 500.0K -33% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Shares 2024-09-23 M A 250,000 $3.85 459,322 D — —
2 Common Common Shares 2024-09-20 F D 3,087 $11.97 209,322 D — — (F1) Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
3 Common Common Shares 2024-09-23 S D 250,000 $11.89 209,322 D — — (F2) The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
4 Derivative Stock Option (Right to Buy) 2024-09-23 M D 250,000 $0.00 500,000 D $3.85 · — to 2032-04-19 250,000 Common Stock (F3) Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).